News
Top 7 drug-free solutions for managing PMS and PMDD in in 2025
Have you noticed how some weeks you feel focused and energetic, while other weeks bring brain fog, pain, and mood swings that feel impossible to manage?
For the estimated 90 per cent of women who experience premenstrual syndrome (PMS) and the 5-8 per cent living with premenstrual dysphoric disorder (PMDD), monthly symptoms aren’t just inconvenient; they’re life-disrupting.
Traditional approaches often default to pharmaceutical interventions: birth control pills, antidepressants, or pain medications. But what if your body is asking for something different?
In 2025, drug-free PMDD treatment and natural menstrual relief options have moved from alternative corners into mainstream science, backed by clinical research and measurable outcomes.
Understanding PMS and PMDD: What Your Brain Is Really Doing
Before jumping into solutions, it’s worth understanding what’s actually happening. PMS and PMDD aren’t just hormonal. They’re brain-based responses to hormonal fluctuations.
PMS (Premenstrual Syndrome) involves physical and emotional symptoms in the week or two before menstruation: breast tenderness, bloating, irritability, fatigue, and mood changes.
PMDD (Premenstrual Dysphoric Disorder) affects 5-8 per cent of menstruating individuals with debilitating mood symptoms: severe depression, anxiety, anger, and hopelessness.
Many with PMDD are told they’re just emotional, when the reality is their brain is responding intensely to normal hormonal shifts.
Research shows that estrogen and progesterone affect brain connectivity and even brain volume in regions connected to memory, mood, and pain.
This isn’t weakness. It’s neuroscience.
The top 7 Drug-Free Solutions for Managing PMS and PMDD are:
1. Neurostimulation Technology: Brain-First Relief for Menstrual Symptoms
The most promising advancement in drug-free PMDD treatment comes from neurotechnology. Transcranial direct current stimulation (tDCS) delivers gentle electrical currents to specific brain regions involved in mood regulation and pain processing.
Clinical studies demonstrate that neuromodulation can reduce menstrual pain and improve low mood symptoms without hormones or systemic side effects.
By working directly on neural circuits, it addresses symptoms at their control centre rather than masking them.
Neurostimulation takes advantage of neuroplasticity — the brain’s ability to rewire and strengthen itself. When you consistently activate certain neural pathways, you can actually change how your brain processes pain signals and regulates mood.
Wearable devices designed specifically for menstrual health now bring this technology home.
Users typically wear the device for 20 minutes daily during specific cycle phases.
No appointments, no pharmacy visits.
Samphire’s Nettle™ represents this brain-first approach: a CE-certified medical device that has shown clinical effectiveness in reducing menstrual-related pain and mood symptoms.
It’s hormone-free and drug-free, making it compatible with existing treatments or as a standalone solution.
2. Targeted Nutritional Support: Food as Medicine for Natural Menstrual Relief
What you eat directly impacts inflammation, neurotransmitter production, and hormonal metabolism. Certain nutrients have been clinically shown to reduce PMS and PMDD symptoms.
Nutrient | Daily Dose | Primary Benefit | Food Sources |
Magnesium | 200-400mg | Reduces cramping, improves mood | Dark leafy greens, pumpkin seeds, dark chocolate |
Vitamin B6 | 50-100mg | Supports serotonin production | Chickpeas, salmon, potatoes, bananas |
Calcium | 1,000-1,200mg | Decreases mood swings and pain | Dairy, fortified plant milk, sardines, kale |
Omega-3 Fatty Acids | 1-2g EPA/DHA | Reduces inflammation and depression | Fatty fish, walnuts, flaxseed |
Vitamin D | 1,000-2,000 IU | Regulates mood and immune function | Fortified foods (e.g., dairy and non-dairy milks), supplements |
Magnesium supplementation reduces PMS symptoms by 30-40 per cent.
Vitamin B6, when taken consistently, has shown particular effectiveness for mood-related symptoms because it helps convert tryptophan into serotonin, your brain’s primary mood-regulating neurotransmitter.
3. Cycle-Synced Movement: Exercise That Works With Your Brain
Exercise is often recommended for PMS, but the type and intensity matter significantly.
Your brain responds differently to movement across your cycle.
Follicular Phase (Days 1-14): Rising estrogen levels increase pain tolerance and support muscle building. This is when high-intensity interval training and strength training feel most manageable.
Luteal Phase (Days 15-28): As progesterone rises and estrogen drops, your body shifts toward a more inflammatory state. Moderate-intensity movement, such as yoga, walking, and swimming, reduces PMDD symptoms more effectively than high-intensity training during this phase.
4. Cognitive Behavioural Therapy and Mind-Body Techniques for Drug-Free PMS Management
Cognitive behavioural therapy (CBT) has emerged as one of the most effective drug-free PMDD treatment approaches, with clinical trials showing results comparable to antidepressant medications for some individuals.
PMDD often involves thought patterns that intensify emotional responses. CBT helps identify and restructure these patterns before they spiral. Accessible mind-body practices include:
- Breathwork: Slow, diaphragmatic breathing activates the parasympathetic nervous system, reducing anxiety and pain perception
- Mindfulness meditation: Studies show 8 weeks of consistent practice increases grey matter in brain regions connected to emotional regulation
- Progressive muscle relaxation: Systematically tensing and releasing muscle groups reduces physical tension and mental stress
5. Strategic Sleep Optimisation: Reset Your Brain’s Control Centre
Sleep disruption is both a symptom and a cause of worsening PMS and PMDD. Progesterone metabolites have sedative effects, which is why some women feel more tired during their luteal phase.
Key Sleep Strategies:
- Keep bedroom temperature 2-3 degrees cooler during the luteal phase (progesterone raises body temperature)
- Avoid caffeine after 2 PM
- Use blackout curtains or eye masks
- Consider magnesium glycinate 1-2 hours before bed
- Maintain consistent sleep-wake times even during symptomatic phases
6. Anti-Inflammatory Nutrition Patterns for Natural Menstrual Relief
Chronic low-grade inflammation worsens both pain and mood symptoms.
The Mediterranean diet consistently shows benefits for menstrual health due to its anti-inflammatory profile.
Foods to Prioritise:
- Colourful vegetables (5-7 servings daily)
- Berries and cherries (high in anthocyanins)
- Fatty fish 2-3 times weekly
- Extra virgin olive oil
- Nuts and seeds
- Turmeric and ginger
Foods to Minimise:
- Refined sugars and processed foods
- Trans fats and hydrogenated oils
- Excessive alcohol
- High sodium intake during the luteal phase
7. Herbal Supplements: Traditional Medicine Meets Modern Science
Certain botanicals have demonstrated clinical effectiveness for natural menstrual relief, with safety profiles that make them viable long-term options.
Vitex (Chasteberry): Multiple studies show vitex reduces PMS symptoms by 50% or more by influencing dopamine receptors. Typical dose: 20-40mg daily.
Evening Primrose Oil: Contains gamma-linolenic acid (GLA), an omega-6 fatty acid that reduces inflammatory prostaglandins. Typical dose: 500-1,000mg twice daily during the luteal phase.
Saffron: A 2020 randomised controlled trial found saffron extract (30mg daily) reduced PMDD symptoms comparably to fluoxetine with fewer side effects.
Ginger: Studies demonstrate ginger’s effectiveness for menstrual pain, with some trials showing results equivalent to ibuprofen. Typical dose: 250mg four times daily during menstruation.
Building Your Personalised Drug-Free PMDD Treatment Plan
The most effective approach rarely involves just one solution.
Combining strategies typically yields better results than any single intervention.
Getting Started:
- Track symptoms across at least two full cycles
- Implement sleep optimisation and basic nutrition changes first
- Add one targeted intervention (neurostimulation, supplements, or mind-body practices) based on your primary symptoms
- Assess which interventions created the most improvement after 2-3 cycles
The Brain-First Approach: Why This Matters
Every hormonal change starts in the brain. The hypothalamus releases signals that trigger the pituitary, which then signals the ovaries.
This is why brain-first interventions, whether neurostimulation, CBT, sleep optimisation, or strategic nutrition, can create lasting change.
Understanding your cycle patterns and how your brain responds in each phase provides insight that makes everything else more effective.
You’re not just managing symptoms.
You’re giving your brain the support it needs to regulate responses more effectively.
A hormone sensor being developed in Australia could help reduce fertility treatment costs and patient pain during IVF.
When preparing for egg collection or an embryo transfer, IVF patients rely on clinicians to closely monitor hormone levels to ensure the procedure is timed precisely when progesterone, oestradiol and luteinising hormone levels are optimal, giving the patient the best chance at conception.
Currently, blood tests are the primary method of measuring progesterone levels, requiring patients to undergo multiple blood draws at a laboratory during certain stages of their menstrual cycle.
However, this approach has several limitations.
For example, if testing falls on a weekend, when most labs are closed, IVF providers are forced to choose a less optimal testing time, potentially affecting treatment precision.
University of Melbourne alumni Edgar Charry and Muhammad Umer, whose partners have lived experience of infertility, created a reproductive health solution by developing a biosensor that can detect progesterone and oestradiol levels using fluid found in the skin, rather than in the blood.
Their startup company Symex Labs has partnered with the University of Melbourne to translate their research into a commercial product.
“Previous research shows nearly all hormones that exist in blood, are also present in interstitial fluid,” said Symex Labs co-founder Charry.
“Interstitial fluid is clear fluid just under the skin that sits between cells, delivering nutrients and carrying away waste.”
“Our biosensor will eventually be worn as a patch and will work by penetrating the skin using small microneedles to attract progesterone molecules in the patient’s interstitial fluid.
“These molecules will bind to the surface of the probe, generating electrical activity. The technology then translates the electrical activity to progesterone levels, ultimately informing the IVF clinical team if the patient is ready for embryo transfer.
“This data will be sent directly to the clinic’s monitoring system, allowing IVF nurses to review the results and advise the patient.”
Monash IVF research director associate professor Mark Green said that, for Monash IVF, the investment in Symex Labs aligns with the company’s focus on innovation and improving the patient journey.
“This technology will save patients time and money as they can conveniently wear the patch in the comfort of their own home, resulting in fewer visits to the clinic and fewer painful injections,” associate professor Green said.
“The biosensor would also be a gamechanger for women living in regional areas, who often have to travel long distances for blood draws.”
As the exact amount of progesterone in interstitial fluid is not well understood, Symex Labs is conducting a world-first clinical study at Monash IVF to establish baseline levels by benchmarking them against concentrations measured in blood samples.
Researchers say their hormone tracking technology also has wider clinical applications beyond the IVF sector.
“Our wearable hormone biosensor has strong potential well beyond fertility care, particularly in PCOS management, perimenopause and menopause symptom management, where continuous hormone insight can replace today’s indirect, symptom-based tracking,” said Symex Labs co-founder Muhammad Umer.
“By integrating directly with consumer health apps, the technology can enable personalised, data-driven management of chronic hormonal conditions and life-stage transitions that currently lack real-time biomarkers.
“For example, if a woman’s oestrogen is going up and down constantly, that’s often a sign that she is getting into that stage, so having access to this health information could help women implement lifestyle changes earlier.”
The research has received A$2.5m in funding from the federal government, the University of Melbourne’s Genesis fund, Monash IVF, RMIT and Breakthrough Victoria.
The first in-human pilot study is expected to get underway within the next 12 months, with commercialisation plans slated for early 2028.
Pregnancy complications may leave women more vulnerable to the long-term heart effects of stress, a recent study suggests.
A study of more than 3,000 women in their first pregnancy found persistently higher stress levels were associated with higher blood pressure after pregnancy, specifically in women who had adverse pregnancy outcomes including preeclampsia, preterm birth, having a baby that was small for gestational age, meaning smaller than expected for that stage of pregnancy, or stillbirth.
Among women who experienced these complications, higher stress levels over time were associated with blood pressure that was 2 mm Hg higher than that of the low-stress group during the years two to seven after delivery.
This was not the case among women who did not experience adverse pregnancy outcomes.
Virginia Nuckols, lead author of the study and a postdoctoral fellow in the University of Delaware’s department of kinesiology and applied physiology, said: “For women who were having babies for the first time and had complications, referred to as adverse pregnancy outcomes, we found that higher stress levels over time were associated with higher blood pressure levels 2-to-7 years after delivery.
“This suggests that women who had pregnancy complications may be more susceptible to the negative effects of stress on their heart health, and taking steps to manage and reduce stress could be important for protecting long-term heart health.”
The researchers analysed records of 3,322 first-time mothers aged 15 to 44 who did not have high blood pressure before pregnancy.
The women were enrolled at 17 medical centres in eight US states, were pregnant with one baby and were having their first child. According to the authors, 66 per cent of participants self-identified as white, 14 per cent as Hispanic and 11 per cent as Black.
Blood pressure and stress levels were measured during the first and third trimesters, and again two to seven years after delivery.
Stress was assessed using the Perceived Stress Scale, a standard questionnaire that asks how often people feel situations are uncontrollable, unpredictable or overwhelming.
Those who experienced moderate to high stress levels were often younger, between 25 and 27 years of age, had higher body mass index, a measure based on height and weight, and lower educational attainment.
The authors said it is not yet clear exactly how higher stress leads to higher blood pressure in women who had pregnancy complications, and that several factors are likely to be involved.
Nuckols added: “Future studies should examine why women with a history of adverse pregnancy outcomes may be more susceptible to stress-driven increases in blood pressure and test whether stress reduction interventions can actually lower cardiovascular risk for these women.”
High blood pressure during pregnancy can have lasting effects on maternal health, including preeclampsia, eclampsia, stroke or kidney problems, according to the American Heart Association’s 2025 guideline for the prevention, detection, evaluation and management of high blood pressure in adults.
Monitoring blood pressure before, during and after pregnancy is crucial to help prevent and reduce the risk of long-term complications.
Laxmi Mehta is chair of the American Heart Association’s Council on Clinical Cardiology and director of preventive cardiology and women’s cardiovascular health at The Ohio State University Wexner Medical Center, and was not involved in the study.
Mehta said;’ “This study highlights the powerful connection between the mind and heart, emphasising the importance of stress management, particularly for those who have experienced adverse pregnancy outcomes.
“For the clinical care team, it reinforces the need to proactively assess and address stress as part of the comprehensive care we provide to our patients.
“Future research on whether targeted interventions to reduce or manage stress has a meaningful impact on long-term cardiovascular outcomes will be important as well.”
AI could help routine mammograms spot heart disease risk in women, as well as breast cancer, researchers have found.
A team from Emory University analysed regular screening scans from more than 123,000 women who had no prior history of cardiovascular disease.
Using an AI programme to quantify calcification and hardening in the arteries, they found women with severe cases had two to three times the risk of developing potentially fatal heart attacks, stroke and heart failure.
“This was true even in younger women under 50, a group often considered low-risk, and held up after accounting for other risk factors like diabetes and smoking,” said Hari Trivedi, Emory associate professor and co-director of the university’s Health Innovation and Translational Informatics lab, who described the research as the largest study of its kind.
“We wanted to test whether AI could use this to identify women at risk of cardiovascular disease at no extra cost or inconvenience.
“”For women, this means a mammogram you’re already having could also provide important information about your heart health, prompting a conversation with your doctor about preventive steps such as cholesterol testing or medication.”
The researchers’ work was published today in the European Heart Journal, from the European Society of Cardiology, which noted that women are largely underdiagnosed and undertreated for cardiovascular disease.
They wrote that the high resolution of routine mammograms could allow for essentially automatic, direct visualisation of the arterial beds within the breasts of nearly all adult women, with calcifications easy to detect and correlated with deposits found in other parts of the body.
The researchers said that, compared with imaging of the heart’s coronary arteries, where blockages narrow and impede the flow of oxygenated blood to the heart muscle, calcifications in breast tissue affect a separate layer of the vessel, resulting in increased artery stiffness, a measure typically linked to long-term hypertension.
They described the finding as an independent predictor of cardiovascular disease and a potentially useful addition to traditional cardiovascular risk factors.
In an accompanying editorial, Lori Daniels, a cardiologist and professor of medicine at the UC San Diego School of Medicine, said that while fewer than 40 per cent of women may know their cholesterol levels, many more are up to date with their breast cancer screening.
“Two-thirds of women aged 50-69 in the European Union reported a mammogram within the prior 2 years, and in the USA, nearly 70 per cent of women aged 45 years and older were up to date with mammography according to American Cancer Society screening guidelines,” Daniels wrote.
“Breast arterial calcification has the potential to reframe this mismatch, leveraging a widely adopted cancer-screening platform to identify cardiovascular risk in women who may not otherwise engage with prevention.”
Fertility4 weeks agoFrance urges 29-year-olds to start families now
Menopause4 weeks agoWomen with ADHD almost twice as likely to experience perimenopause symptoms, study finds
Fertility4 weeks agoKindbody unveils next-gen fertility platform
Entrepreneur2 weeks agoOura launches women’s health AI model
Menopause4 weeks agoMenopause specialist Haver joins Midi Health
Opinion4 weeks agoThe $128b paradox: Corporate wellness vs women’s burnout
Entrepreneur4 weeks agoKate Ryder headlines Women’s Health Week USA 2026 as full agenda goes live
Insight2 weeks agoWomen’s HealthX launches in Boston this December to transform women’s health through data and science
2 Comments